Leprosy MCQ Quiz | Infectious Diseases – Mycobacterial

Welcome to the Leprosy MCQ Quiz, specifically designed for MBBS students navigating the complexities of Infectious Diseases. This comprehensive assessment covers crucial aspects of leprosy, from its causative agent, Mycobacterium leprae, to its diverse clinical presentations under the Ridley-Jopling and WHO classifications. Test your knowledge on the cardinal signs, the immunopathology of lepra reactions, diagnostic methods like slit-skin smears, and the principles of Multi-Drug Therapy (MDT) for both paucibacillary and multibacillary cases. This quiz will challenge your understanding of nerve involvement, potential deformities, and management strategies. Upon completion, you will receive your score and can review the correct answers. For your revision, a downloadable PDF with all questions and answers is also available.

1. What is the causative agent of leprosy?

2. Which of the following is NOT considered a cardinal sign for the diagnosis of leprosy?

3. In the Ridley-Jopling classification of leprosy, which pole represents the highest cell-mediated immunity?

4. The most widely accepted mode of transmission for Mycobacterium leprae is:

5. Type 1 lepra reaction (Reversal Reaction) is a manifestation of:

6. Erythema Nodosum Leprosum (ENL) is characteristic of which condition?

7. What is the primary purpose of the Bacteriological Index (BI) in a slit-skin smear?

8. Which peripheral nerve is most commonly affected in leprosy, leading to a “claw hand” deformity?

9. According to the WHO operational classification, a patient with 4 skin lesions and no positive slit-skin smear is classified as:

10. The standard WHO multi-drug therapy (MDT) regimen for Paucibacillary (PB) leprosy in adults consists of:

11. What is the duration of the standard WHO MDT regimen for Multibacillary (MB) leprosy?

12. In the MDT for MB leprosy, Clofazimine is included primarily for its:

13. The Lepromin test (Mitsuda reaction) is primarily used for:

14. The Morphological Index (MI) in a slit-skin smear is a measure of:

15. A patient with diffuse, symmetrical skin infiltration, numerous nodules, madarosis (loss of eyebrows), and a high BI on slit-skin smear likely has:

16. The first-line treatment for a severe Type 1 Lepra Reaction (Reversal Reaction) is:

17. The drug of choice for managing severe Erythema Nodosum Leprosum (ENL), especially in non-pregnant patients, is:

18. Nerve damage in Tuberculoid (TT) leprosy is primarily caused by:

19. The Lucio phenomenon, a rare necrotizing erythema, is most associated with which form of leprosy?

20. The recommended treatment for a single skin lesion paucibacillary (SLPB) leprosy is:

21. A major dose-related side effect of Dapsone, particularly in patients with G6PD deficiency, is:

22. A characteristic side effect of Rifampicin that patients should be counseled about is:

23. A leprosy patient is considered “cured” or “Released From Treatment” (RFT) when they have:

24. What is the characteristic histopathological finding in a skin biopsy of Tuberculoid Leprosy (TT)?

25. A diagnosis of Pure Neuritic Leprosy (PNL) is made when a patient presents with:

Author

  • G S Sachin Author Pharmacy Freak
    : Author

    G S Sachin is a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. He holds a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research and creates clear, accurate educational content on pharmacology, drug mechanisms of action, pharmacist learning, and GPAT exam preparation.

    Mail- Sachin@pharmacyfreak.com

PRO
Ad-Free Access
$3.99 / month
  • ✓ No Interruptions
  • ✓ Faster Page Loads
  • ✓ Support Content Creators
Subscribe Now